Alector, Inc. (ALEC) vs Lyell Immunopharma, Inc. (LYEL)

Alector, Inc. and Lyell Immunopharma, Inc. are both Biotechnology companies. Alector, Inc. and Lyell Immunopharma, Inc. are of similar size ($411.8M and $376.7M). Lyell Immunopharma, Inc. has negative trailing earnings, so its P/E is not meaningful; Alector, Inc. trades at 7.1×. Alector, Inc. grew revenue faster over the last twelve months: 151.2% against −63.4%. Alector, Inc. has the higher net margin (23.9% vs −1,701,066.7%) and the higher return on invested capital (0.00% vs −1,070.8%). Across the 16 metrics below, Alector, Inc. leads on 12 and Lyell Immunopharma, Inc. on 4.

Valuation

Metric ALEC LYEL Biotechnology median
P/E 7.06 n/m 10.96
P/S 1.61 27,335.74 9.52
P/B 2.40 2.13 2.23
Price to free cash flow n/m n/m 25.69
EV/EBITDA 3.89 n/m 0.68
EV/Sales 0.92 15,528.67 9.00
Earnings yield 14.16% (74.87%) (32.09%)
Free cash flow yield (53.54%) (44.17%) (22.62%)

Profitability

Metric ALEC LYEL Biotechnology median
Gross margin 100.00% 100.00% 68.51%
Operating margin 20.16% (1,783,580.00%) 0.00%
Net margin 23.87% (1,701,066.67%) 0.00%
Free cash flow margin (86.31%) (1,207,540.00%) 0.00%
Return on equity 47.52% (97.79%) (50.12%)
Return on assets 16.53% (74.85%) (45.12%)
Return on invested capital 0.00% (1,070.83%) 0.00%

Growth

Metric ALEC LYEL Biotechnology median
Revenue growth (TTM) 151.23% (63.41%) 6.78%
EPS growth (last fiscal year) (13.01%) 38.70% 29.88%
Revenue growth, 5-year CAGR (0.05%) (65.85%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALEC LYEL Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.10 4.02 4.74
Net debt to EBITDA 1.61 0.94 1.01

Dividend

Metric ALEC LYEL Biotechnology median
Dividend yield — — 0.40%
Payout ratio — — —

Size

Metric ALEC LYEL Biotechnology median
Market cap 376.66m 411.81m 166.39m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack